Ignite Creation Date:
2024-05-05 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00408473
Status:
TERMINATED
Last Update Posted:
2022-02-07
First Post:
2006-12-06
Brief Title:
Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation
Sponsor:
MEDA Pharma GmbH Co KG
Organization:
Viatris Inc
Study Overview
Official Title:
A Randomised Double-blind Pilot Study Comparing Flecainide CR and Placebo in the Early Treatment of Patients With a Documented First Episode of Atrial Fibrillation
Status:
TERMINATED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the efficacy of flecainide controlled release CR in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None